Welcome to the Innovative Psychiatric

Get Started

What we offer

Treating Depression
Over 21 million Americans are affected by Major Depressive Disorder. Regrettably, nearly half of those who undergo treatment with antidepressant medications do not experience a sufficient response. The FDA defines Treatment Resistant Depression (TRD) as a condition where patients fail to adequately respond to two distinct antidepressants of appropriate dosage and duration.
Contact us
The Treatment
SPRAVATO is a nasal spray containing Esketamine for treating depression. Patients self-administer the spray under a healthcare professional's supervision, who monitors them for 2 hours per FDA guidelines. The treatment has two phases: Initiation (twice a week for four weeks) and Maintenance (weekly or biweekly). Our patient pods offer a comfortable setting with HD TVs and reclining chairs. Studies show SPRAVATO provides positive results without long-term serious side effects, abuse potential, or significant weight gain or sexual side effects
Contact us
Opening Hours
Monday – Friday
(9:00 AM – 5:00 PM)

Contact Us

SPRAVATO – In 2019, the FDA grantedapproval for Spravato (Esketamine) totreat Treatment Resistant Depression (TRD). Initially approved as an anesthetic agent in 1970, ketamine was later discovered to have a rapid and potent antidepressant effect when administered intravenously. Notably, Spravato is an intranasal formulation, that is patient administered under supervision. It became the first and only form of ketamine approved for use in treating depression. To find out more visit:

Spravato
Specializing in spravato, a breakthrough treatment for treatment-resistant depression
Office
Office Hour
  • Monday – Friday
  • 9:00 AM – 5:00 PM
  • Saturday – Sunday
  • Closed
© 2023 All Rights Reserved | Designed with ❤ by Blue-IT Technologies